Epidemiology of Hypertension in CKD

Advances in Chronic Kidney Disease

Volumn 22, Issue 2, 2015, Pages 88-95

  Horowitz, Bruce ^a,b,c   Miskulin, Dana ^a,b,c   Zager, Philip ^a,b,c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b TUFTS UNIVERSITY   (United States)

^c Dialysis Clinic Inc   (United States)

Author keywords

Chronic kidney disease; Epidemiology; Health disparities; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN C3; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ALBUMINURIA; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; ETHNICITY; GENETIC POLYMORPHISM; HAZARD RATIO; HEMODIALYSIS PATIENT; HEREDITY; HISPANIC; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIFESTYLE; ONSET AGE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SEX DIFFERENCE; SOCIAL STATUS; SODIUM EXCRETION; SODIUM INTAKE; SODIUM URINE LEVEL; TREATMENT FAILURE; BLOOD PRESSURE MEASUREMENT; COMPLICATION; DISEASE MANAGEMENT; ETHNIC GROUP; ETHNOLOGY; KIDNEY FUNCTION TEST; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

ADULT; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; DISEASE MANAGEMENT; DISEASE PROGRESSION; ETHNIC GROUPS; HUMANS; HYPERTENSION; KIDNEY FUNCTION TESTS; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

EID: 84923842183     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.09.004     Document Type: Review

References (103)

1. James P.A., Oparil S., Carter B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311(5):507-520.
2. Levey A.S., Coresh J., Greene T., et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145(4):247-254.
3. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150(9):604-612.
4. Yoon S.S., Burt V., Louis T., Carroll MD. Hypertension among adults in the United States, 2009-2010. NCHS Data Brief 2012, 107:1-8.
5. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298(17):2038-2047.
6. 2. Am J Kidney Dis 2010, 56(3):486-495.
7. Buckalew V.M., Berg R.L., Wang S.R., Porush J.G., Rauch S., Schulman G. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1996, 28(6):811-821.
8. Whaley-Connell A.T., Sowers J.R., Stevens L.A., et al. CKD in the United States: kidney early evaluation program (KEEP) and national health and nutrition examination survey (NHANES) 1999-2004. Am J Kidney Dis 2008, 51(4 suppl 2):S13-S20.
9. Hsu C.C., Kao W.H., Coresh J., et al. Apolipoprotein E and progression of chronic kidney disease. JAMA 2005, 293(23):2892-2899.
10. Ghattas M., Badaway H., Mesbah N., Abo-Ematty D. Apolipoprotein CIII3238C/G gene polymorphism influences oxidized low-density lipoprotein with a risk of essential hypertension. J Biochem Pharmacol Res 2013, 1(3):143-147.
11. Renal Data System USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2013, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, Accessed June 11, 2014. http://www.usrds.org/adr.aspx.
12. Muntner P., Anderson A., Charleston J., et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2010, 55(3):441-451.
13. Jurkovitz C.T., Qiu Y., Wang C., Gilbertson D.T., Brown W.W. The Kidney Early Evaluation Program (KEEP): program design and demographic characteristics of the population. Am J Kidney Dis 2008, 51(4 suppl 2):S3-S12.
14. Kalaitzidis R., Li S., Wang C., et al. Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2009, 53(4 suppl 4):S22-S31.
15. Rao M.V., Qiu Y., Wang C., Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis 2008, 51(4 suppl 2):S30-S37.
16. Zheng Y., Cai G.Y., Chen X.M., et al. Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients. Chin Med J (Engl) 2013, 126(12):2276-2280.
17. Singh A.K., Farag Y.M., Mittal B.V., et al. Epidemiology and risk factors of chronic kidney disease in India-results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol 2013, 14:114.
18. Obrador G.T., Garcia-Garcia G., Villa A.R., et al. Prevalence of chronic kidney disease in the Kidney Early Evaluation Program (KEEP) Mexico and comparison with KEEP US. Kidney Int Suppl 2010, 116:S2-S8.
19. Agarwal R., Andersen M.J. Correlates of systolic hypertension in patients with chronic kidney disease. Hypertension 2005, 46(3):514-520.
20. Ridao N., Luno J., Garcia d V., Gomez F., Tejedor A., Valderrabano F. Prevalence of hypertension in renal disease. Nephrol Dial Transplant 2001, 16(suppl 1):70-73.
21. Inker L.A., Coresh J., Levey A.S., Tonelli M., Muntner P. Estimated GFR, albuminuria, and complications of chronic kidney disease. J Am Soc Nephrol 2011, 22(12):2322-2331.
22. Peralta C.A., Hicks L.S., Chertow G.M., et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension 2005, 45(6):1119-1124.
23. Renal Data System USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2012, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, Accessed June 11, 2014. http://www.usrds.org/atlas12.aspx.
24. Peralta C.A., Shlipak M.G., Fan D., et al. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol 2006, 17(10):2892-2899.
25. Ferdinand K.C. Hypertension in minority populations: new guidelines and emerging concepts. Adv Chronic Kidney Dis 2015, 22(2):145-153.
26. Ferguson R., Grim C.E., Opgenorth T.J. A familial risk of chronic renal failure among blacks on dialysis?. J Clin Epidemiol 1988, 41(12):1189-1196.
27. Lipkowitz M.S., Freedman B.I., Langefeld C.D., et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013, 83(1):114-120.
28. Kao W.H., Klag M.J., Meoni L.A., et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008, 40(10):1185-1192.
29. Kopp J.B., Smith M.W., Nelson G.W., et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40(10):1175-1184.
30. Nelson G.W., Freedman B.I., Bowden D.W., et al. Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. Hum Mol Genet 2010, 19(9):1805-1815.
31. Madhavan S.M., O'Toole J.F., Konieczkowski M., et al. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 2011, 22(11):2119-2128.
32. Genovese G., Friedman D.J., Ross M.D., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 329(5993):841-845.
33. Tzur S., Rosset S., Skorecki K., Wasser W.G. APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. Nephrol Dial Transplant 2012, 27(4):1498-1505.
34. Freedman B.I., Sedor J.R. Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008, 19(11):2047-2051.
35. Yamamoto M.E., Olson M.B., Fine J., Powers S., Stollar C. The effect of sodium restriction and weight reduction on blood pressure of patients with hypertension and chronic renal disease. J Ren Nutr 1997, 7(1):25-32. [Abstract].
36. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51(6):1403-1419.
37. Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011, 57(6):1076-1080.
38. De N.L., Gabbai F.B., Agarwal R., et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 2013, 61(24):2461-2467.
39. Egan B.M., Zhao Y., Axon R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303(20):2043-2050.
40. Sarafidis P.A., Li S., Chen S.C., et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med 2008, 121(4):332-340.
41. Coresh J., Wei G.L., McQuillan G., et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001, 161(9):1207-1216.
42. Fischer M.J., Go A.S., Lora C.M., et al. CKD in Hispanics: baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC studies. Am J Kidney Dis 2011, 58(2):214-227.
43. Duru O.K., Li S., Jurkovitz C., et al. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2008, 51(2):192-198.
44. Kramer H., Han C., Post W., et al. Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA). Am J Hypertens 2004, 17(10):963-970.
45. Hebert L.A., Kusek J.W., Greene T., et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension 1997, 30(3 pt 1):428-435.
46. Altun B., Suleymanlar G., Utas C., et al. Prevalence, awareness, treatment and control of hypertension in adults with chronic kidney disease in Turkey: results from the CREDIT study. Kidney Blood Press Res 2012, 36(1):36-46.
47. Renal Data System USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2010, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, Accessed June 12, 2014. http://www.usrds.org/atlas10.aspx.
48. Gu Q., Burt V.L., Dillon C.F., Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health and Nutrition Examination Survey, 2001 to 2010. Circulation 2012, 126(17):2105-2114.
49. Lazarus J.M., Hampers C., Merrill J.P. Hypertension in chronic renal failure. Treatment with hemodialysis and nephrectomy. Arch Intern Med 1974, 133(6):1059-1066.
50. Jacobsen P., Rossing K., Tarnow L., et al. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int Suppl 1999, 71:S101-S105.
51. Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994, 330(13):877-884.
52. Fogo A., Breyer J.A., Smith M.C., et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) trial. AASK Pilot Study Investigators. Kidney Int 1997, 51(1):244-252.
53. Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati F.L., Stamler J. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997, 277(16):1293-1298.
54. Klag M.J., Whelton P.K., Randall B.L., et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334(1):13-18.
55. Flack J.M., Neaton J.D., Daniels B., Esunge P. Ethnicity and renal disease: lessons from the multiple risk factor intervention trial and the treatment of mild hypertension study. Am J Kidney Dis 1993, 21(4 suppl 1):31-40.
56. Whelton P.K., Klag M.J. Hypertension as a risk factor for renal disease. Review of clinical and epidemiological evidence. Hypertension 1989, 13(5 suppl):I19-I27.
57. Lewis J.B., Berl T., Bain R.P., Rohde R.D., Lewis E.J. Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis 1999, 34(5):809-817.
58. Jafar T.H., Stark P.C., Schmid C.H., et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003, 139(4):244-252.
59. Pohl M.A., Blumenthal S., Cordonnier D.J., et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005, 16(10):3027-3037.
60. Wright J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288(19):2421-2431.
61. Hsu C.Y., Lin F., Vittinghoff E., Shlipak M.G. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 2003, 14(11):2902-2907.
62. Kannel W.B., Gordon T., Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 1969, 71(1):89-105.
63. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360(9349):1903-1913.
64. Wolf P.A., D'Agostino R.B., Belanger A.J., Kannel W.B. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991, 22(3):312-318.
65. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003, 42(6):1206-1252.
66. Kovesdy C.P., Lu J.L., Molnar M.Z., et al. Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. JAMA Intern Med 2014, 174(9):1442-1449.
67. Sim J.J., Shi J., Kovesdy C.P., Kalantar-Zadeh K., Jacobsen S.J. Impact of Achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol 2014, 64(6):588-597.
68. Agarwal R., Nissenson A.R., Batlle D., Coyne D.W., Trout J.R., Warnock D.G. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003, 115(4):291-297.
69. Heerspink H.J., Ninomiya T., Zoungas S., et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009, 373(9668):1009-1015.
70. Rohrscheib M.R., Myers O.B., Servilla K.S., et al. Age-related blood pressure patterns and blood pressure variability among hemodialysis patients. Clin J Am Soc Nephrol 2008, 3(5):1407-1414.
71. Shafi T., Sozio S.M., Bandeen-Roche K.J., et al. Predialysis systolic BP variability and outcomes in hemodialysis patients. J Am Soc Nephrol 2014, 25(4):799-809.
72. St Peter W.L., Sozio S.M., Shafi T., et al. Patterns in blood pressure medication use in US incident dialysis patients over the first 6 months. BMC Nephrol 2013, 14:249.
73. Agarwal R., Sinha A.D. Meta-analysis-not proof but call for action. Hypertension 2009, 54(1):e7.
74. Davenport A., Cox C., Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int 2008, 73(6):759-764.
75. Port F.K., Hulbert-Shearon T.E., Wolfe R.A., et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999, 33(3):507-517.
76. Tentori F., Karaboyas A., Robinson B.M., et al. Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2013, 62(4):738-746.
77. Zager P.G., Nikolic J., Brown R.H., et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998, 54(2):561-569.
78. Blumberg A., Nelp W.B., Hegstrom R.M., Scribner B.H. Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction. Lancet 1967, 2(7506):69-73.
79. Converse R.L., Jacobsen T.N., Toto R.D., et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992, 327(27):1912-1918.
80. Dorhout Mees E.J. Hypertension in haemodialysis patients: who cares?. Nephrol Dial Transplant 1999, 14(1):28-30.
81. Fagugli R.M., Reboldi G., Quintaliani G., et al. Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 2001, 38(2):371-376.
82. Katzarski K.S., Charra B., Luik A.J., et al. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 1999, 14(2):369-375.
83. Lins R.L., Elseviers M., Rogiers P., et al. Importance of volume factors in dialysis related hypertension. Clin Nephrol 1997, 48(1):29-33.
84. Luik A.J., Sande F.M., Weideman P., Cheriex E., Kooman J.P., Leunissen K.M. The influence of increasing dialysis treatment time and reducing dry weight on blood pressure control in hemodialysis patients: a prospective study. Am J Nephrol 2001, 21(6):471-478.
85. Sanders P.W. Assessment and treatment of hypertension in dialysis: the case for salt restriction. Semin Dial 2007, 20(5):408-411.
86. Scribner B.H. A personalized history of chronic hemodialysis. Am J Kidney Dis 1990, 16(6):511-519.
87. Vertes V., Cangiano J.L., Berman L.B., Gould A. Hypertension in end-stage renal disease. N Engl J Med 1969, 280(18):978-981.
88. Wilson J., Shah T., Nissenson A.R. Role of sodium and volume in the pathogenesis of hypertension in hemodialysis. Semin Dial 2004, 17(4):260-264.
89. Agarwal R., Alborzi P., Satyan S., Light R.P. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009, 53(3):500-507.
90. Fagugli R.M., Pasini P., Quintaliani G., et al. Association between extracellular water, left ventricular mass and hypertension in haemodialysis patients. Nephrol Dial Transplant 2003, 18(11):2332-2338.
91. Krautzig S., Janssen U., Koch K.M., Granolleras C., Shaldon S. Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance haemodialysis patients. Nephrol Dial Transplant 1998, 13(3):552-553.
92. Ozkahya M., Toz H., Qzerkan F., Asci G., Ok E. Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol 2002, 15(6):655-660.
93. Toz H., Ozkahya M., Ozerkan F., et al. Improvement in "uremic" cardiomyopathy by persistent ultrafiltration. Hemodial Int 2007, 11(1):46-50.
94. Gul A., Miskulin D., Gassman J., et al. Design of the blood pressure goals in dialysis pilot study. Am J Med Sci 2014, 347(2):125-130.
95. Agarwal R. Home and ambulatory blood pressure monitoring in chronic kidney disease. Curr Opin Nephrol Hypertens 2009, 18(6):507-512.
96. Buoncristiani U., Quintaliani G., Cozzari M., Giombini L., Ragaiolo M. Daily dialysis: long-term clinical metabolic results. Kidney Int Suppl 1988, 24:S137-S140.
97. Chan C.T., Floras J.S., Miller J.A., Richardson R.M., Pierratos A. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002, 61(6):2235-2239.
98. Chan C.T., Harvey P.J., Picton P., Pierratos A., Miller J.A., Floras J.S. Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 2003, 42(5):925-931.
99. Chertow G.M., Levin N.W., Beck G.J., et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010, 363(24):2287-2300.
100. Nesrallah G., Suri R., Moist L., Kortas C., Lindsay R.M. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis 2003, 42(1 suppl):13-17.
101. Rocco M.V., Lockridge R.S., Beck G.J., et al. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int 2011, 80(10):1080-1091.
102. Ting G.O., Kjellstrand C., Freitas T., Carrie B.J., Zarghamee S. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis 2003, 42(5):1020-1035.
103. Zilch O., Vos P.F., Oey P.L., et al. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. J Hypertens 2007, 25(6):1285-1289.